Business
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
All participants in the Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well
About this update from Immunitybio, Inc.
[{"type":"text","content":"\n\nAll participants in the Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well tolerated\n\n\n\nN-803 is being studied in three other HIV cure-related clinical trials\n\n\n\n CULVER CITY, Calif.--(BUSINESS WIRE)--\nImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced data from a Phase 1 pilot study showed N-803 combined with natural killer cells could have the potential to reduce viral load in people living with HIV.\n\n\nPublished in The Journal of Infectious Diseases, researchers at the University of Minnesota Medical School gave six HIV-positive individuals infusions of healthy NK cells from close relatives, along with N-803 to boost NK cell activity. All participants in this Phase 1 study experienced significant reduction in infection levels following treatment with N-803. The approach was well tolerated with no unexpected adverse events.\n\n\nTim Schacker, MD, senior author of this paper, and colleagues at the University of Minnesota Medical School are planning a follow-on study in additional participants to further investigate these immunotherapies in HIV infected individuals.\n\n\nHIV affects tens of millions globally and currently has no known cure. HIV can disable NK cells—a frontline defense against viral infections—making it difficult to clear the infection. One current strategy for curing HIV is known as the \"kick and kill\" approach. N-803 is under evaluation using this strategy, given the molecule’s ability to activate viral transcription in CD4+ T cells (\"kick\") and boost CD8+ and NK cells, crucial for identifying and eliminating infected cells (\"kill\"), directing them to viral reservoirs.\n\n\n\"Antiretroviral therapies have had a profound impact on society, making it possible for those living with HIV to live longer lives with better outcomes. However, these therapies are not a cure, and still place a significant burden on people living with the HIV virus and the healthcare system,” said Patrick Soon-Shiong, M.D., Chairman and Global Chief Scientific and Medical Officer at ImmunityBio. “These data preliminarily appear to validate what we know about the benefit of enhancing NK cell function and the potential utility of N-803 in infectious diseases.”\n\n\nIn addition to this study, three other clinical ...